featured
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
J. Clin. Oncol 2020 Dec 09;[EPub Ahead of Print], PG Richardson, A Oriol, A Larocca, J Bladé, M Cavo, P Rodriguez-Otero, X Leleu, O Nadeem, JW Hiemenz, H Hassoun, C Touzeau, A Alegre, A Paner, C Maisel, A Mazumder, A Raptis, JS Moreb, KC Anderson, JP Laubach, S Thuresson, M Thuresson, C Byrne, J Harmenberg, NA Bakker, MV MateosFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.